CRISPR Gene Therapy in India: Cost, Reimbursement & Equity Challenges (2026)
This article analyses the promise of CRISPR therapies and the challenges of affordability, reimbursement, and equitable access in India
CRISPR Gene Therapies Have Arrived: India's Cost, Reimbursement, and Equity Crisis Remains
Introduction
CRISPR-based gene therapies have ushered in a new era of medicine, offering the possibility of functional cures for inherited blood disorders such as sickle cell disease and beta-thalassemia. Unlike conventional treatments that manage symptoms throughout a patient's life, these therapies aim to correct the underlying genetic defect with a single intervention.
However, while the science has reached a historic milestone, India's healthcare system faces significant challenges in making these therapies accessible. High treatment costs, limited reimbursement mechanisms, manufacturing barriers, and healthcare inequities continue to prevent most Indian patients from benefiting from these breakthroughs.
CRISPR Gene Therapy: A Historic Medical Breakthrough
The approval of CRISPR-based therapies marks one of the most important advances in modern medicine. Patients with severe sickle cell disease and transfusion-dependent beta-thalassemia have demonstrated remarkable improvements in clinical trials, with many becoming transfusion-free and experiencing dramatic reductions in disease-related complications.
This represents a shift from lifelong disease management to the possibility of long-term functional cure.
Why CRISPR Gene Therapy Is Currently Unaffordable in India
International Pricing Creates an Immediate Barrier
Approved CRISPR therapies currently rank among the world's most expensive medical treatments.
- Casgevy launched at approximately US$2.2 million per patient
- Lyfgenia entered the market at around US$3.1 million
These costs reflect individualized manufacturing, complex cell processing, advanced laboratory infrastructure, and years of research investment.
For India, however, these prices remain far beyond the reach of nearly every household, making access practically impossible despite clinical success.
India's Large Disease Burden Makes Access More Urgent
India carries one of the world's largest populations affected by inherited blood disorders.
Sickle Cell Disease
- Approximately 20 million carriers
- Highest prevalence among tribal populations in central and western India
- Supported through the National Sickle Cell Anaemia Elimination Mission, aiming for elimination by 2047
Beta-Thalassemia
- More than 100,000 children are born annually with severe disease requiring lifelong treatment.
Most patients currently depend on:
- Regular blood transfusions
- Hydroxyurea therapy
- Iron chelation therapy
- Bone marrow transplantation for eligible patients
While gene therapy promises a one-time curative approach, access remains largely theoretical for Indian patients.
India's Reimbursement System Is Not Designed for Gene Therapy
Public Insurance Faces Major Limitations
India's existing reimbursement models were developed for conventional healthcare expenses rather than ultra-high-cost curative therapies.
Current challenges include:
- Ayushman Bharat coverage of approximately ₹5 lakh per family annually
- No outcomes-based payment models
- No installment-based reimbursement system
- No dedicated pathway for million-dollar therapies
As a result, approved gene therapies remain outside the financial scope of existing government insurance schemes.
Can Compulsory Licensing Solve the Problem?
India has previously used compulsory licensing to improve access to expensive medicines.
However, gene therapies present a different challenge.
Why Gene Therapy Is Different
Unlike traditional pharmaceutical drugs, CRISPR therapies require:
- Advanced cell-processing laboratories
- Viral vector manufacturing
- Sophisticated quality-control systems
- Highly specialized clinical infrastructure
Even with patent flexibility, India currently lacks sufficient manufacturing capacity to produce these therapies at scale.
What India Is Doing to Prepare
Although commercial access remains limited, India is investing in long-term capabilities.
Current initiatives include:
Research and Development
- ICMR-supported gene therapy research
- Department of Biotechnology funding for advanced therapies
- Domestic clinical programs for beta-thalassemia
Genomics Infrastructure
Projects like IndiGen are strengthening India's precision medicine ecosystem by building population-specific genomic databases.
Alternative Curative Approaches
Several institutions are expanding haploidentical bone marrow transplantation, which offers curative potential at substantially lower costs than gene therapy.
For many patients today, improving access to transplantation may deliver greater population-level benefits than waiting for affordable CRISPR therapies.
The Equity Challenge Beyond Cost
The debate around gene therapy often focuses on pricing.
The larger issue is equitable access.
Many of the diseases targeted by CRISPR therapies disproportionately affect populations in India, sub-Saharan Africa, and other low-resource settings. Yet the healthcare systems most capable of delivering these therapies remain concentrated in wealthier countries.
Scientific innovation alone does not guarantee equitable healthcare access.
What India Needs Next
Several priorities could improve future accessibility.
Build Domestic Manufacturing
India should expand advanced cell and gene therapy manufacturing through targeted investment and public-private partnerships.
Strengthen Regulatory Frameworks
Clear and predictable approval pathways can encourage domestic innovation and global investment.
Modernize Reimbursement Models
Future healthcare financing should explore:
- Outcomes-based payments
- Installment reimbursement models
- Public-private funding mechanisms
Invest in India-Specific Research
Developing therapies suited to India's healthcare infrastructure and economic realities will be essential for long-term sustainability.
Conclusion
CRISPR gene therapies represent one of the greatest scientific achievements in modern medicine. They offer genuine hope for patients living with severe inherited blood disorders.
Yet in India, the greatest challenge is no longer scientific feasibility—it is affordability, healthcare financing, manufacturing capacity, and equitable access.
Until these structural barriers are addressed, the promise of gene editing will remain available to only a small fraction of the patients who need it most.
Team Healthvoice
#CRISPRTherapy #HealthEquity
